Verastem, Inc. VSTM
9.09 USD +0.36 (+4.12%)
At closeNov 11, 2026, 4:00 PM EST
9.09 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
8.68 Day range 9.22
3.43 52-week range 10.82
- YTD
- +17.75%
- 1 year
- +7.57%
News
marketbeat.com Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path Verastem NASDAQ: VSTM plans to advance a 900-milligram dose of its experimental KRAS G12D inhibitor VS-7375 across cancer indications, citing evidence of a dose response and a tolerability profile…
marketbeat.com Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans Verastem NASDAQ: VSTM is advancing its experimental KRAS G12D inhibitor VS-7375 toward potential accelerated approval in pancreatic cancer, with plans to expand studies in colorectal and lung…
marketbeat.com What Verastem (VSTM) Said on Its Q3 Earnings Call Verastem NASDAQ: VSTM reported $24 million in third-quarter 2026 net product revenue as refills of its ovarian cancer treatment offset a moderation in new patient starts. The company also outlined…
seekingalpha.com Verastem, Inc. (VSTM) Q3 2026 Earnings Call Transcript Verastem, Inc. ( VSTM ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Julissa Viana - Senior Vice President of Corporate Communications, Investor Relations & Patient…
benzinga.com RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $18 RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $19 to $18.
benzinga.com HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $20 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $18 to $20.
zacks.com Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates Verastem (VSTM) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to a loss of $1.35 per share a year ago.
benzinga.com Verastem Oncology Q3 2026 Earnings Call Transcript Verastem Oncology (NASDAQ:VSTM) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Verastem Oncology Files $100M At-The-Market Equity Offering Agreement With Cantor Fitzgerald This registration statement contains the following documents:• a base prospectus, which covers the offering, issuance and sale by us of an indeterminate amount of the securities identified below from…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.
benzinga.com Verastem Q3 Adj. EPS $(0.72) Misses $(0.46) Estimate, Sales $24.012M Miss $26.078M Estimate Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.46) by 56.52 percent. This is a 33.33 percent decrease over losses of $(0.54)…
businesswire.com Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial…
businesswire.com Verastem Oncology to Participate in Upcoming November Investor Conferences BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its…
businesswire.com Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026 BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the…- benzinga.com Mizuho Maintains Outperform on Verastem, Raises Price Target to $14 Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and raises the price target from $13 to $14.
benzinga.com Jefferies Maintains Buy on Verastem, Raises Price Target to $13 Jefferies analyst Faisal Khurshid maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $11 to $13.
benzinga.com RBC Capital Maintains Outperform on Verastem, Raises Price Target to $19 RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and raises the price target from $14 to $19.- benzinga.com Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.
benzinga.com BTIG Maintains Buy on Verastem, Raises Price Target to $24 BTIG analyst Jeet Mukherjee maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $18 to $24.
seekingalpha.com Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript
marketbeat.com Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III Verastem NASDAQ: VSTM presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ongoing TARGET-D 101 study in patients with pancreatic ductal…
benzinga.com Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers Verastem Oncology (NASDAQ:VSTM) reported encouraging early clinical results for its experimental KRAS G12D inhibitor VS-7375, with the drug demonstrating antitumor activity across pancreatic,…
benzinga.com Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers Verastem Oncology reports promising VS-7375 response rates in pancreatic, colorectal, and lung cancers, with a Phase 3 trial planned for 2026.
benzinga.com Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
barrons.com Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.- benzinga.com Verastem Oncology Appoints Michael P. Bailey As President And CEO, Effective January 1, 2027 Mr. Bailey will also continue to serve on the Company’s Board of Directors. The CEO transition follows the planned retirement of Daniel Paterson, who will step down as President and CEO and continue…
benzinga.com Verastem Oncology Announces Initial Data In First Multi-Tumor Update From Ongoing TARGET-D 101 Phase 1/2 Clinical Trial Evaluating VS-7375; Data Demonstrate Robust Clinical Activity With Favorable Safety And Tolerability Profile Across Multiple Dose Levels And Tumor Types VS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L; responses are durable with a…
businesswire.com Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed…
businesswire.com Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that…
businesswire.com VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 demonstrates robust clinical activity with favorable safety and tolerability in KRAS G12D-mutated pancreatic, lung and colorectal cancers.
zacks.com Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect? The consensus price target hints at a 79% upside potential for Verastem (VSTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…- benzinga.com Verastem Oncology Q2 2026 Earnings Call Transcript Verastem Oncology (NASDAQ:VSTM) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…
benzinga.com BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.
seekingalpha.com Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch Verastem is performing commercially with Avmapki Fakzynja Co-pack and advancing in the clinic with its KRAS G12D inhibitor, VS-7375, in multiple cancers. Q2 '26 net product revenues reached $25.1M in…
businesswire.com Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the…
defenseworld.net Verastem (NASDAQ:VSTM) Given Buy Rating at BTIG Research Verastem (NASDAQ: VSTM - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at BTIG Research in a research note issued to investors on Monday, Benzinga reports. They currently…
defenseworld.net HC Wainwright Reaffirms “Buy” Rating for Verastem (NASDAQ:VSTM) Verastem (NASDAQ: VSTM - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a report released on Monday, MarketBeat Ratings reports. They presently have a…
benzinga.com HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.- benzinga.com Verastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026 RAMP 201 molecular profiling showed clinically meaningful activity in KRAS wild-type recurrent LGSOC, including ORRs of 22% in patients with NRAS- or BRAF-mutated tumors and 18% in patients with…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
benzinga.com Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ETVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with…- benzinga.com Mizuho Maintains Outperform on Verastem, Lowers Price Target to $13 Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $14 to $13.
- benzinga.com Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12 Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $14 to $12.
- benzinga.com Verastem Q2 Adj. EPS $(0.35) Beats $(0.43) Estimate, Sales $25.078M Beat $23.093M Estimate Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.43) by 18.6 percent. This is a 44.44 percent increase over losses of $(0.63) per…
- benzinga.com Verastem Oncology Doses First Participant In Its TARGET-D 203 Phase 2 Study Of VS-7375 To Treat Metastatic Colorectal Cancer Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Tenet Healthcare (NYSE:THC) shares rose 14.1% to $227.06 during Thursday's after-market session. The company's market cap stands at $17.1 billion. As per the news, the Q2 earnings report came…- benzinga.com Verastem Oncology Doses First Patient In Phase 2 Trial Of VS-7375 For KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer And Untreated Asymptomatic Untreated Brain Metastases TARGET-D 202 (NCT07659782) is a global, open-label, Phase 2 registration-directed trial evaluating VS-7375 monotherapy at the recommended Phase 2 dose (RP2D) of 900 mg daily (QD) in patients with…
benzinga.com These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.- benzinga.com RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14 RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $15 to $14.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.